FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209996850> ?p ?o ?g. }

• W3209996850 abstract "Abstract Introduction Immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologics are not well studied. The goal of this study is to measure serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receiving different biologic therapies. Method We performed a multi-center prospective study between August 1 st , 2021, and September 15 th , 2021. We measured seropositivity of SARS-CoV2 antibodies, SARS-CoV-2 IgG and neutralizing antibody concentrations, in patients with IBD receiving biologic therapies between 4–10 weeks after second dose or 3-6 weeks after first dose of vaccination with BNT162b2 or ChAdOx1 nCoV-19 vaccines. Results There were 126 patients enrolled (mean age, 31 years; 60% male; 71% Crohn’s disease, 29% ulcerative colitis). 92 patients were vaccinated with BNT162b2 vaccine (73%) and 34 patients with ChAdOx1 nCoV-19 vaccine (27%). The proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving 2 doses of the vaccine in patients treated with infliximab and adalimumab were 44 out of 59 patients (74.5%) and 13 out of 16 patients (81.2%), respectively. Whereas the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine in patients treated with ustekinumab and vedolizumab were 100% and 92.8%, respectively. In patients receiving infliximab and adalimumab, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels after two-dose vaccination was 40 out of 59 patients (67.7%) and 14 out 16 patients (87.5%), respectively. Whereas the proportions of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels were 12 out of 13 patients (92.3%) and 13 out of 14 patients (92.8%) in patients receiving ustekinumab and vedolizumab. Conclusion The majority of patients with IBD on infliximab, adalimumab, and vedolizumab seroconverted after two doses of SARS-CoV-2 vaccination. All patients on ustekinumab seroconverted after two doses of SARS-CoV-2 vaccine. BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 are both likely to be effective after two doses in patients with IBD on biologics. A follow up larger studies are needed to evaluate if decay of antibodies occurs over time." @default.
• W3209996850 created "2021-11-08" @default.
• W3209996850 creator A5007130952 @default.
• W3209996850 creator A5007987942 @default.
• W3209996850 creator A5016445054 @default.
• W3209996850 creator A5017854943 @default.
• W3209996850 creator A5022645608 @default.
• W3209996850 creator A5034741700 @default.
• W3209996850 creator A5036936439 @default.
• W3209996850 creator A5043319972 @default.
• W3209996850 creator A5043950009 @default.
• W3209996850 creator A5050404504 @default.
• W3209996850 creator A5051751261 @default.
• W3209996850 creator A5076487680 @default.
• W3209996850 creator A5080368536 @default.
• W3209996850 creator A5089607039 @default.
• W3209996850 date "2021-11-01" @default.
• W3209996850 modified "2023-09-23" @default.
• W3209996850 title "Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies; A Multi-Center Prospective Study" @default.
• W3209996850 cites W1989167852 @default.
• W3209996850 cites W2102116540 @default.
• W3209996850 cites W2556315980 @default.
• W3209996850 cites W2797152839 @default.
• W3209996850 cites W2905751446 @default.
• W3209996850 cites W3014673464 @default.
• W3209996850 cites W3042833857 @default.
• W3209996850 cites W3111255098 @default.
• W3209996850 cites W3112213940 @default.
• W3209996850 cites W3125034838 @default.
• W3209996850 cites W3156839630 @default.
• W3209996850 cites W3158750369 @default.
• W3209996850 cites W3163785571 @default.
• W3209996850 cites W3164041179 @default.
• W3209996850 cites W3164094536 @default.
• W3209996850 cites W3171535338 @default.
• W3209996850 cites W3178085759 @default.
• W3209996850 cites W3191277151 @default.
• W3209996850 cites W3197081215 @default.
• W3209996850 cites W3211309411 @default.
• W3209996850 cites W4225636140 @default.
• W3209996850 cites W4294116629 @default.
• W3209996850 doi "https://doi.org/10.1101/2021.10.31.21265718" @default.
• W3209996850 hasPublicationYear "2021" @default.
• W3209996850 type Work @default.
• W3209996850 sameAs 3209996850 @default.
• W3209996850 citedByCount "5" @default.
• W3209996850 countsByYear W32099968502021 @default.
• W3209996850 countsByYear W32099968502022 @default.
• W3209996850 crossrefType "posted-content" @default.
• W3209996850 hasAuthorship W3209996850A5007130952 @default.
• W3209996850 hasAuthorship W3209996850A5007987942 @default.
• W3209996850 hasAuthorship W3209996850A5016445054 @default.
• W3209996850 hasAuthorship W3209996850A5017854943 @default.
• W3209996850 hasAuthorship W3209996850A5022645608 @default.
• W3209996850 hasAuthorship W3209996850A5034741700 @default.
• W3209996850 hasAuthorship W3209996850A5036936439 @default.
• W3209996850 hasAuthorship W3209996850A5043319972 @default.
• W3209996850 hasAuthorship W3209996850A5043950009 @default.
• W3209996850 hasAuthorship W3209996850A5050404504 @default.
• W3209996850 hasAuthorship W3209996850A5051751261 @default.
• W3209996850 hasAuthorship W3209996850A5076487680 @default.
• W3209996850 hasAuthorship W3209996850A5080368536 @default.
• W3209996850 hasAuthorship W3209996850A5089607039 @default.
• W3209996850 hasBestOaLocation W32099968501 @default.
• W3209996850 hasConcept C126322002 @default.
• W3209996850 hasConcept C159654299 @default.
• W3209996850 hasConcept C203014093 @default.
• W3209996850 hasConcept C22070199 @default.
• W3209996850 hasConcept C2777138892 @default.
• W3209996850 hasConcept C2778260677 @default.
• W3209996850 hasConcept C2779134260 @default.
• W3209996850 hasConcept C2780132546 @default.
• W3209996850 hasConcept C2780479503 @default.
• W3209996850 hasConcept C2780868878 @default.
• W3209996850 hasConcept C45189115 @default.
• W3209996850 hasConcept C71924100 @default.
• W3209996850 hasConcept C90924648 @default.
• W3209996850 hasConceptScore W3209996850C126322002 @default.
• W3209996850 hasConceptScore W3209996850C159654299 @default.
• W3209996850 hasConceptScore W3209996850C203014093 @default.
• W3209996850 hasConceptScore W3209996850C22070199 @default.
• W3209996850 hasConceptScore W3209996850C2777138892 @default.
• W3209996850 hasConceptScore W3209996850C2778260677 @default.
• W3209996850 hasConceptScore W3209996850C2779134260 @default.
• W3209996850 hasConceptScore W3209996850C2780132546 @default.
• W3209996850 hasConceptScore W3209996850C2780479503 @default.
• W3209996850 hasConceptScore W3209996850C2780868878 @default.
• W3209996850 hasConceptScore W3209996850C45189115 @default.
• W3209996850 hasConceptScore W3209996850C71924100 @default.
• W3209996850 hasConceptScore W3209996850C90924648 @default.
• W3209996850 hasLocation W32099968501 @default.
• W3209996850 hasOpenAccess W3209996850 @default.
• W3209996850 hasPrimaryLocation W32099968501 @default.
• W3209996850 hasRelatedWork W1708680437 @default.
• W3209996850 hasRelatedWork W1968760412 @default.
• W3209996850 hasRelatedWork W2001393134 @default.
• W3209996850 hasRelatedWork W2187503363 @default.
• W3209996850 hasRelatedWork W2296926020 @default.
• W3209996850 hasRelatedWork W2297514571 @default.
• W3209996850 hasRelatedWork W2419464638 @default.

• next